KALV
KalVista Pharmaceuticals, Inc.
Biotechnology
Market Cap$1.37B
5Y Perf.+137.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
KALV vs AGEN
Revenue, margins, valuation, and 5-year total return — side by side.
AGEN
Agenus Inc.
Biotechnology
Market Cap$132M
5Y Perf.-95.0%
KALV vs AGEN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KALV | AGEN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.37B | $132M |
| Revenue (TTM) | $15M | $114M |
| Net Income (TTM) | $-210M | $115K |
| Gross Margin | -17.2% | 35.7% |
| Operating Margin | -13.4% | -17.7% |
| Forward P/E | — | 1.8x |
| Total Debt | $6M | $10M |
| Cash & Equiv. | $99M | $3M |
KALV vs AGEN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KALV
AGEN
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| KalVista Pharmaceut… (KALV) | 100 | 237.5 | +137.5% |
| Agenus Inc. (AGEN) | 100 | 5.0 | -95.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KALV vs AGEN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: AGEN leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. KalVista Pharmaceuticals, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
KALV
KalVista Pharmaceuticals, Inc.
The Income Pick
KALV is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.82
- 154.5% 10Y total return vs AGEN's -94.3%
- Lower volatility, beta 0.82, Low D/E 6.6%, current ratio 5.35x
Best for: income & stability and long-term compounding
AGEN
Agenus Inc.
The Growth Play
AGEN carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 10.4%, EPS growth 100.0%, 3Y rev CAGR 5.2%
- 10.4% revenue growth vs KALV's -34.5%
- 0.1% margin vs KALV's -13.9%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AGEN | 10.4% revenue growth vs KALV's -34.5% |
| Quality / Margins | AGEN | 0.1% margin vs KALV's -13.9% |
| Stability / Safety | KALV | Beta 0.82 vs AGEN's 2.72 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | KALV | +118.1% vs AGEN's +27.1% |
| Efficiency (ROA) | AGEN | 0.1% ROA vs KALV's -77.7% |
KALV vs AGEN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
KALV vs AGEN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAGENLAGGINGKALV
KALVKalVista Pharmaceutic…
2leads
AGENAgenus Inc.
3leads
6 Total Categories
CATEGORYLEADERvs KALVMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AGEN5/5
Valuation MetricsMultiples, price ratios, and targets
AGEN1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
AGEN3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
KALV6/6
Risk & VolatilityBeta, volatility, and downside exposure
KALV2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
AGEN leads this category, winning 5 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
AGEN is the larger business by revenue, generating $114M annually — 7.6x KALV's $15M. AGEN is the more profitable business, keeping 0.1% of every revenue dollar as net income compared to KALV's -13.9%.
| Metric | KALVKalVista Pharmace… | AGENAgenus Inc. |
|---|---|---|
| RevenueTrailing 12 months | $15M | $114M |
| EBITDAEarnings before interest/tax | -$202M | -$10M |
| Net IncomeAfter-tax profit | -$210M | $115,000 |
| Free Cash FlowCash after capex | -$160M | -$159M |
| Gross MarginGross profit ÷ Revenue | -17.2% | +35.7% |
| Operating MarginEBIT ÷ Revenue | -13.4% | -17.7% |
| Net MarginNet income ÷ Revenue | -13.9% | +0.1% |
| FCF MarginFCF ÷ Revenue | -10.6% | -139.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +27.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -1.1% | +85.3% |
AGEN leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
AGEN leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | KALVKalVista Pharmace… | AGENAgenus Inc. |
|---|---|---|
| Market CapShares × price | $1.4B | $132M |
| Enterprise ValueMkt cap + debt − cash | $1.3B | $140M |
| Trailing P/EPrice ÷ TTM EPS | -7.24x | -1102.94x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 1.79x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 1.16x |
| Price / BookPrice ÷ Book value/share | 13.91x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
AGEN leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
AGEN leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), AGEN scores 6/9 vs KALV's 2/9, reflecting solid financial health.
| Metric | KALVKalVista Pharmace… | AGENAgenus Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -2.8% | — |
| ROA (TTM)Return on assets | -77.7% | +0.1% |
| ROICReturn on invested capital | -152.3% | — |
| ROCEReturn on capital employed | -89.9% | — |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 |
| Debt / EquityFinancial leverage | 0.07x | — |
| Net DebtTotal debt minus cash | -$92M | $7M |
| Cash & Equiv.Liquid assets | $99M | $3M |
| Total DebtShort + long-term debt | $6M | $10M |
| Interest CoverageEBIT ÷ Interest expense | -13.75x | 1.11x |
AGEN leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
KALV leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KALV five years ago would be worth $10,595 today (with dividends reinvested), compared to $611 for AGEN. Over the past 12 months, KALV leads with a +118.1% total return vs AGEN's +27.1%. The 3-year compound annual growth rate (CAGR) favors KALV at 41.0% vs AGEN's -51.0% — a key indicator of consistent wealth creation.
| Metric | KALVKalVista Pharmace… | AGENAgenus Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +72.8% | +16.1% |
| 1-Year ReturnPast 12 months | +118.1% | +27.1% |
| 3-Year ReturnCumulative with dividends | +180.1% | -88.2% |
| 5-Year ReturnCumulative with dividends | +5.9% | -93.9% |
| 10-Year ReturnCumulative with dividends | +154.5% | -94.3% |
| CAGR (3Y)Annualised 3-year return | +41.0% | -51.0% |
KALV leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
KALV leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KALV is the less volatile stock with a 0.82 beta — it tends to amplify market swings less than AGEN's 2.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KALV currently trades 99.5% from its 52-week high vs AGEN's 51.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KALVKalVista Pharmace… | AGENAgenus Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.82x | 2.72x |
| 52-Week HighHighest price in past year | $26.84 | $7.34 |
| 52-Week LowLowest price in past year | $9.83 | $2.71 |
| % of 52W HighCurrent price vs 52-week peak | +99.5% | +51.1% |
| RSI (14)Momentum oscillator 0–100 | 75.4 | 48.8 |
| Avg Volume (50D)Average daily shares traded | 3.0M | 814K |
KALV leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates KALV as "Buy" and AGEN as "Buy". Consensus price targets imply 95.5% upside for AGEN (target: $7) vs 6.7% for KALV (target: $29).
| Metric | KALVKalVista Pharmace… | AGENAgenus Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $28.50 | $7.33 |
| # AnalystsCovering analysts | 13 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% |
Insufficient data to determine a leader in this category.
Key Takeaway
AGEN leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). KALV leads in 2 (Total Returns, Risk & Volatility).
Best OverallAgenus Inc. (AGEN)Leads 3 of 6 categories
Loading custom metrics...
KALV vs AGEN: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is KALV or AGEN a better buy right now?
Analysts rate KalVista Pharmaceuticals, Inc.
(KALV) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KALV or AGEN?
Over the past 5 years, KalVista Pharmaceuticals, Inc.
(KALV) delivered a total return of +5. 9%, compared to -93. 9% for Agenus Inc. (AGEN). Over 10 years, the gap is even starker: KALV returned +154. 5% versus AGEN's -94. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KALV or AGEN?
By beta (market sensitivity over 5 years), KalVista Pharmaceuticals, Inc.
(KALV) is the lower-risk stock at 0. 82β versus Agenus Inc. 's 2. 72β — meaning AGEN is approximately 230% more volatile than KALV relative to the S&P 500.
04Which is growing faster — KALV or AGEN?
On earnings-per-share growth, the picture is similar: Agenus Inc.
grew EPS 100. 0% year-over-year, compared to -7. 3% for KalVista Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — KALV or AGEN?
Agenus Inc.
(AGEN) is the more profitable company, earning 0. 1% net margin versus -1391. 1% for KalVista Pharmaceuticals, Inc. — meaning it keeps 0. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AGEN leads at -18. 0% versus -1343. 0% for KALV. At the gross margin level — before operating expenses — AGEN leads at 90. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is KALV or AGEN more undervalued right now?
Analyst consensus price targets imply the most upside for AGEN: 95.
5% to $7. 33.
07Which pays a better dividend — KALV or AGEN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is KALV or AGEN better for a retirement portfolio?
For long-horizon retirement investors, KalVista Pharmaceuticals, Inc.
(KALV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 82), +154. 5% 10Y return). Agenus Inc. (AGEN) carries a higher beta of 2. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KALV: +154. 5%, AGEN: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between KALV and AGEN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.